Brought to you by 
NuPathe closes $30mm Series B round
Jul 2008
Executive Summary
NuPathe (transdermal patch and implantable drug delivery technologies for CNS conditions) raised $30mm through a Series B round that was led by Quaker BioVentures and GlaxoSmithKline's venture arm SR One. Previous backers Safeguard Scientifics, Bay City Capital/Birchmere Ventures, Battelle Ventures, and BioAdvance Ventures also participated. A principal from SR One will join NuPathe's board.
Deal Industry
- Biotechnology
-
Medical Devices
- Biomaterials
- Implantable Devices
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Transdermal
- Specialty Pharmaceuticals
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NuPathe closes $30mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice